recurrent ovarian caricinoma
Conditions
Interventions
study duration: 2014.11-2019.10 chemotherapy rejimenn: PTX+CBDCA+Bev Administration Period:until PD
Doc+CBDCA+Bev
GEM+CBDCA+Bev
PLD+CBDCA+Bev
Irinotecan+CDDP+Bev
PTX+Bev
Doc+Bev
GEM+Bev
PLD+Bev
Iri
Sponsors
Yokohama city univesity Obstetrics and Gynecology
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) histological, cytological diagnosed epithelial ovarian cancer,primary fallopian tube cancer,peritoneal cancer (2)has performed simple hysterectomy+bilateral salpingo-oophorectomy +p-omentectomy (3)after front line therapy and has obtained CR(including during mentainance therapy of bevacizumab),has relapsed at first (4)chemoterapy rejimen before this treatment is until 3 rejimen (5)PS 0-1 (6)measurable lesion of the criteria of RECIST,or/and non-mesurable lesion of cancerous ascites and pleural effusion (7)has held patients function of major organs(such as bone marrow/hear/liver/kidney) (8)expected survibal >3 months (9)has obtained informed consent
Exclusion criteria
Exclusion criteria: (1)Patients with serious complications(such as uncontrolled diabetes) (2)Patients with below such severe heart disease congestive heart failure uncontrolled arrhythmia uncontrolled hypertension angina pectoris valvular heart disease (3)Patients with abdominal fistula of history, gastrointestinal perforation, intra-abdominal abscess,the symptoms of intestinal obstruction can not been able oral nutrition not-healing wounds, ulcers,fractions bleeding diathesis and significant coagulopathy Period of up to study treatment start from major surgery effective date is in the next 28 days,it is in the urine protein +2 or more at the time and registration (4) Patients with interstitial pneumonia or pulmonary fibrosis (5)patients with a history of severe drug hypersensitivity and drug allergy (6)Other, patients attending physician has determined that inadequate to safely carry out the present study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event of bevacizumab response rate | — |
Countries
Japan
Contacts
Public ContactTatsuya Matsunaga
Yokohama city univesity Obstetrics and Gynecology
Outcome results
None listed